MADRID, 23 Oct. (EUROPA PRESS) –
The Swiss laboratory Roche has signed a definitive agreement to acquire Telavant Holdings, a company owned 75% by Roivant Sciences and 25% by Pfizer, for 7.1 billion dollars (6.7 billion euros), including the rights to development, manufacturing and commercialization in the US and Japan of RVT-3101, a new experimental therapy for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.
Under the terms of the agreement, Roche will pay a purchase price of $7.1 billion up front and a short-term milestone payment of another $150 million (€141 million).
Following the closing of the transaction, Roche will have all rights to develop and manufacture RVT-3101 and commercialize it in the US and Japan pending clinical and regulatory results, while outside the US and Japan, the rights to Marketing corresponds to Pfizer.
“We are excited to add this promising new therapy in development to our portfolio and make it available to patients as quickly as possible,” said Thomas Schinecker, CEO of the Roche Group. .
“We believe RVT-3101 has the potential to be the first therapy that offers high efficacy and safety for people with inflammatory bowel disease,” added Levi Garraway, Roche’s chief medical officer and head of global product development.
